Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

  • End date
    Nov 21, 2023
  • participants needed
  • sponsor
    Hebei Senlang Biotechnology Inc., Ltd.
Updated on 21 March 2022


This is an open, single-arm, prospective clinical study to evaluate the safety and efficacy of anti CD19 and CD22 CAR-T cell in the treatment of R/R B-ALL.


CD19-directed CAR-T cell therapy has shown promising results in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. CD19 and CD22 are proteins usually expressed on the surface of the B leukemia cells. The dual-CARs enables the T-cells to recognize and kill the tumor cell through recognition of CD19 and CD22.

Condition CD19+ and CD 22+ B-ALL
Treatment Cyclophosphamide,Fludarabine, Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
Clinical Study IdentifierNCT05225831
SponsorHebei Senlang Biotechnology Inc., Ltd.
Last Modified on21 March 2022


Yes No Not Sure

Inclusion Criteria

Sign the informed consent and be willing and able to comply with the visit, treatment regimen, laboratory examination and other requirements of the study as stipulated in the trial flow chart
A definite diagnosis of B-cell Lymphocyte Leukemia, which meets any of the following criteria: Relapsed : a) relapsed within 12 months after first remission;Refractory: a) no remission after six weeks of induction therapy or no remission after two courses of induction therapy; b) relapsedafter CR for 2 or more times; c) The first relapse after chemotherapy and no remission after at least one salvage treatment; c) relapsed after hematopoietic stem cell transplantation
ECOG Scores: 0~2
CD19 positive and CD22 positive were detected by immunohistochemistry or flow cytometry
Estimated survival time>3 months
Peripheral blood mononuclear immune cells must be collected at least 2 weeks after the last radiotherapy or systemic treatment
For patients with only extramedullary recurrence of B-ALL, there must be at least one assessable lesion

Exclusion Criteria

Serious cardiac insufficiency;
Has a history of severe pulmonary function damaging
Presence of other malignant tumors
Presence of active fungal, bacterial, viral, or other infection requiring IV antibiotics for management
Presence of other severe autoimmune diseases or immunodeficiency disease
Patients with active hepatitis B or hepatitis C([HBVDNA+]or [HCVRNA+])
Known positive serology for human immunodeficiency virus (HIV) or syphilis。
Has a history of serious allergies on biological products (including antibiotics)
Female patients who are under pregnancy and/or lactation, or planing on pregnancy for the next 12 months
Any other situations that the researchers believe will affect the results of the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note